David C Fajgenbaum Selected Research

David C Fajgenbaum Research Topics

Disease

28	Castleman Disease (Castleman's Disease) 02/2024 - 12/2015
21	Thrombocytopenia (Thrombopenia) 02/2024 - 02/2016
20	Edema (Dropsy) 02/2024 - 02/2016
18	Fever (Fevers) 02/2024 - 02/2016
15	Fibrosis (Cirrhosis) 02/2024 - 02/2016
13	Cytokine Release Syndrome 01/2024 - 05/2014
10	Inflammation (Inflammations) 01/2024 - 11/2018
9	Lymphadenopathy 02/2024 - 04/2016
8	Multi-centric Castleman's Disease 08/2022 - 05/2014
6	Cytopenia 04/2022 - 03/2017
5	Renal Insufficiency (Renal Failure) 01/2024 - 01/2017
5	Thrombocytosis (Thrombocythemia) 01/2024 - 03/2017
4	COVID-19 01/2022 - 01/2020
4	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 05/2017
3	Rare Diseases (Rare Disease) 10/2022 - 12/2015
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 04/2022 - 01/2019
3	Anemia 01/2022 - 03/2017
3	Neoplasms (Cancer) 01/2022 - 01/2020
3	Ascites 11/2021 - 04/2016
2	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 04/2022 - 03/2017
2	Autoimmune Lymphoproliferative Syndrome 01/2022 - 01/2020
2	Hypoalbuminemia 01/2022 - 03/2017
1	Immunoglobulin G4-Related Disease 02/2024
1	Hyperplasia 04/2022
1	Primary Effusion Lymphoma 11/2021
1	Kaposi Sarcoma (Kaposi's Sarcoma) 11/2021
1	POEMS Syndrome (Syndrome, POEMS) 11/2021
1	Communicable Diseases (Infectious Diseases) 10/2021
1	Leukocytosis (Pleocytosis) 02/2020
1	Hypersensitivity (Allergy) 01/2020
1	Histiocytosis 01/2020
1	Hodgkin Disease (Hodgkin's Disease) 01/2019
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2019
1	Disease Progression 01/2018
1	Proteinuria 03/2017
1	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2017
1	Splenomegaly 04/2016
1	Hepatomegaly 04/2016
1	Acute Kidney Injury (Acute Renal Failure) 02/2016
1	Abdominal Pain (Pain, Abdominal) 02/2016
1	Paraneoplastic Syndromes (Paraneoplastic Syndrome) 05/2014

Drug/Important Bio-Agent (IBA)

19	Reticulin (Reticular Fiber)IBA 02/2024 - 02/2016
15	Interleukin-6 (Interleukin 6)IBA 01/2024 - 05/2014
10	CytokinesIBA 10/2022 - 05/2014
7	C-Reactive ProteinIBA 01/2024 - 04/2016
5	siltuximabIBA 10/2022 - 01/2016
3	Sirolimus (Rapamycin)FDA Link 01/2023 - 01/2020
3	Biomarkers (Surrogate Marker)IBA 11/2022 - 12/2021
2	Immunoglobulin G (IgG)IBA 02/2024 - 01/2022
2	AntibodiesIBA 01/2022 - 01/2017
2	AutoantibodiesIBA 01/2021 - 05/2014
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 04/2016
2	Immunoglobulins (Immunoglobulin)IBA 01/2018 - 05/2017
1	Messenger RNA (mRNA)IBA 10/2022
1	COVID-19 VaccinesIBA 10/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	Interferon Type IIBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	tocilizumab (atlizumab)FDA Link 01/2022
1	InterleukinsIBA 09/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 03/2021
1	CreatinineIBA 02/2020
1	AA amyloidosisIBA 02/2020
1	Interleukin-3 (Interleukin 3)IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	Formaldehyde (Formol)FDA Link 01/2019
1	ParaffinIBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Thalidomide (Thalomid)FDA Link 01/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	Prednisone (Sone)FDA LinkGeneric 01/2019
1	Rituximab (Mabthera)FDA Link 09/2018
1	ChemokinesIBA 01/2018
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 04/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2016
1	Alkaline PhosphataseIBA 02/2016
1	NexusIBA 01/2016
1	4- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA 01/2016

Therapy/Procedure

10	Therapeutics 01/2023 - 05/2014
2	Drug Therapy (Chemotherapy) 11/2023 - 04/2016
2	Precision Medicine 01/2019 - 12/2015
1	Immunomodulation 01/2021